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Abstract 
Diabetes mellitus (DM) and essential hypertension are common conditions that are frequently present together. Both 
are considered risk factors for cardiovascular disease and microvascular complications and therefore treatment of 
both conditions is essential. Many papers were published on blood pressure (BP) targets in diabetic patients, includ-
ing several works published in the last 2 years. As a result, guidelines differ in their recommendations on BP targets in 
diabetic patients. The method by which to control hypertension, whether pharmacological or non-pharmacological, 
is also a matter of debate and has been extensively studied in the literature. In recent years, new medications were 
introduced for the treatment of DM, some of which also affect BP and the clinician treating hypertensive and diabetic 
patients should be familiar with these medications and their effect on BP. In this manuscript, we discuss the evidence 
supporting different BP targets in diabetics and review the various guidelines on this topic. In addition, we discuss the 
various options available for the treatment of hypertension in diabetics and the recommendations for a specific treat-
ment over the other. Finally we briefly discuss the new diabetic drug classes and their influence on BP.
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Background
Essential hypertension and diabetes mellitus (DM) are 
both extremely common conditions and therefore it is 
not surprising that their co-existence is extremely preva-
lent. Since both are considered risk factors for coronary 
artery disease, cerebrovascular disease, renal failure and 
congestive heart failure, treatment of both conditions is 
essential. Whether blood pressure (BP) should be low-
ered to a different target in diabetic patients has been a 
debate for many years. Current guidelines are inconsist-
ent regarding BP target in diabetic patients. Whereas sev-
eral guidelines recommend a BP goal of <140/90 mmHg 
[1, 2], some recommend a lower target for diastolic BP 
[3, 4] and some recommend lower systolic BP thresholds 
in certain diabetic population [5–7]. The class of drug 
treatment most appropriate for the treatment of hyper-
tensive diabetics is also unclear and different guidelines 
emphasize use of different drug classes for the treatment 
of hypertension in diabetic patients. Recently introduced 
drug classes for the treatment of DM have also been 
found to lower BP, thus making the interaction between 
BP and DM even more complex. In this review, we dis-
cuss the epidemiology of diabetes and hypertension, the 
benefit of lowering BP in diabetic patients, the target BP 
and the recommended treatment to achieve the target in 
these patients. This review deals mainly with BP control 
in type 2 DM, but some of the data derived from studies 
that included also non diabetic patients.
Epidemiology
Hypertension is twice more common in diabetics than 
in non-diabetics [8], but the definition of hypertension 
in diabetics is generally similar to the general popula-
tions and the threshold for treatment is persistent BP 
values  ≥140/90  mmHg. As both hypertension and DM 
are highly associated with obesity, it is not surprising 
that their co-existence is particularly common in obese 
individuals [9]. Both hypertension and DM increase sig-
nificantly with increasing age and their co-existence is 
highest in older individuals [10]. Patients with DM more 
commonly present with isolated systolic hypertension 
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and are more resistant to treatment. In the EUROASPIRE 
IV survey only 54% of the diabetic patients achieved BP 
levels of less than 140/90  mmHg [11]. In addition, the 
presence of autonomic neuropathy in diabetic patients 
is associated with a less nocturnal BP decrease, a higher 
baseline heart rate and a higher BP variability than in 
non-diabetics [12–18].
The co-existence of DM and hypertension significantly 
increase the risk for coronary heart disease [19], left ven-
tricular hypertrophy [20], congestive heart failure [21] 
and stroke [22] compared with either condition alone. 
In addition, both hypertension and DM are present in 
all prediction models for the occurrence of stroke in 
patients with atrial fibrillation [23–25]. Microvascular 
complications are also more common in patients with co-
existent hypertension and DM and both retinopathy and 
nephropathy are more prevalent in patients with DM and 
hypertension [26, 27]. Lowering BP is particularly benefi-
cial in diabetic patients [28, 29], however how low should 
BP be is controversial.
What should be the blood pressure target in diabetes 
mellitus?
The BP targets in diabetic hypertensive individuals are 
controversial. For many years it was common practice 
to aim for BP targets lower than 130/80 mmHg in non-
proteinuric diabetic patients. This was based on evidence 
from several large studies, including The Hypertension 
Optimal Treatment (HOT) study, the United Kingdom 
Prospective Diabetes Study (UKPDS) 38 and the Action 
in Diabetes and Vascular disease Controlled Evalua-
tion (ADVANCE) trial [29–31]. However, in most stud-
ies the achieved BP was higher than 135/85 mmHg and 
therefore the recommendation to lower BP to less than 
130/80 mmHg was not solid [32, 33]. Moreover, several 
studies reported no benefit and even harm when lower 
BP targets were achieved. In the Ongoing Telmisar-
tan Alone and in Combination with Ramipril Global 
End point Trial (ONTARGET) study, which included 
9612 diabetic patients, the composite primary outcome 
of death from cardiovascular (CV) causes, myocardial 
infarction, stroke, or hospitalization for heart failure did 
not differ between groups despite achievement of lower 
BP values in the telmisartan-ramipril arm [34]. In the 
Prevention Regimen for Effectively Avoiding Second 
Strokes (PROFESS) trial, which included 5743 diabetics, 
recurrence of stroke was not less in patients receiving 
telmisartan despite a significant decrease in BP [35]. The 
PROFESS results were different from those of the Perin-
dopril Protection Against Recurrent Stroke Study Collab-
orative Group (PROGRESS) trial [36], in which treatment 
with the ACE inhibitor perindopril was associated with 
a 38% risk reduction in the occurrence of stroke, but the 
PROGRESS trial included only 762 diabetic patients and 
they were recruited much longer following the initial 
stroke than in the PROFESS trial. The Telmisartan Ran-
domised Assessment Study in ACE Intolerant Subjects 
with CV Disease (TRANSCEND) study [37] was another 
study which 35.7% of the patients were diabetics and in 
which more significant BP reduction with telmisartan 
was not associated with CV benefit.
In the International Verapamil SR/Trandolapril 
(INVEST DM) study there was no difference in short 
term outcome in diabetic patients with coronary artery 
disease despite achievement of significantly lower BP 
(<130  mmHg vs.  <140  mmHg) and in fact, there was 
an increased in the long term all-cause mortality in the 
more tightly controlled group [38]. In the Action to 
Control Cardiovascular Risk in Diabetes Blood Pressure 
(ACCORD-BP) trial, BP reduction to  <120  mmHg did 
not reduce mortality or overall CV outcomes, but did 
reduce significantly only the occurrence of stroke a pre 
specified secondary outcome [39]. Moreover, intensive 
BP lowering was associated with an increased rate of 
syncope and hyperkalemia, both directly related to the 
intensive treatment. The results of this large prospective 
study, in addition to data from other studies, led most of 
the societies to recommend less stringent BP target in 
diabetic patients.
However, the results of the recent systolic blood pres-
sure intervention trial (SPRINT) raised again the discus-
sion what should be the target BP in diabetic patients. 
The SPRINT randomized 9361 persons with systolic 
BP  >  130  mmHg and increased CV risk, but without 
type 2 DM, to a systolic BP target <120 mmHg (intensive 
treatment) or a target of  <140  mmHg (standard treat-
ment). At 1 year, the mean systolic BP was 121.4 mmHg 
in the intensive treatment group and 136.2 mmHg in the 
standard-treatment group. The study was stopped early 
after a median follow-up of 3.26 years owing to 25% lower 
rate of the primary composite outcome in the intensive-
treatment group than in the standard-treatment group 
(P  <  0.001). All-cause mortality was also lower by 27% 
in the intensive treatment group (P  =  0.003) [40]. The 
main benefit was observed in elderly subjects (>75 years) 
who constituted 28% of the study population [41]. Rates 
of serious adverse events of hypotension, syncope, elec-
trolyte abnormalities, and acute kidney injury or failure, 
but not of injurious falls, were higher in the intensive-
treatment group than in the standard-treatment group 
[40]. This recent study supports intensive BP lowering in 
non-diabetic patients with increased CV risk. The most 
important question came from the SPRINT is related to 
diabetic patients who were excluded from this study. In 
light of the discrepancy between the ACCORD and the 
SPRINT can we assume that the better results in SPRINT 
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with intensive BP lowering does not apply to diabetic 
patients?
One approach is to explain why the results of the 
SPRINT should not be applied to diabetic patients and, 
unlike our previous thoughts BP targets in diabetic 
patients should be higher than in non-diabetics. DM has 
a negative influence on arteriolar function and blood flow 
autoregulation that shifts the pressure/flow relationship. 
Therefore diabetic patients are more vulnerable to com-
promised blood flow to vital organs when BP reaches a 
critical low point.
The opposite approach is that the results of the SPRINT 
should be applied to diabetic patients, since in most 
previous trials the benefits of BP reduction in diabetic 
patients were at least as good if not better than in non-
diabetic individuals [29, 42]. To justify this approach one 
should look at the effect of intensive BP lowering in dia-
betic patients on stroke, the long-term follow up results 
of the ACCORD study and the differences between the 
ACCORD and the SPRINT.
In the ACCORD study, despite the failure to show a 
decrease in primary endpoints in the intensive treat-
ment arm the rate of stroke was significantly lower in 
the intensive than in the usual treatment arm [39]. It is 
possible that the ACCORD trial was underpowered, with 
a much lower event rate than anticipated and therefore 
the benefit of intensive BP lowering was not observed. 
Recently, new results from a long-term follow-up of the 
ACCORD patients, dubbed the ACCORDION trial, 
were presented at the 2015 AHA meeting [43]. In this 
extended study 3957 patients were followed for an addi-
tional 54–60 months. During this time, patients who had 
been in the intensive BP arm in the main trial were no 
longer aiming for the lower BP goals, so the difference in 
BP between the two groups narrowed from 14.5 mmHg 
at the end of the main trial to 4.2  mmHg at the end of 
the follow-up period. Results from the follow-up period 
showed a 9% non-significant reduction in the primary 
end point of major CV events over a median follow-up 
of 8.8  years from randomization. During the long-term 
follow-up, an interaction between BP and glycemia inter-
ventions became significant (P for interaction 0.037), 
with evidence of benefit for intensive BP lowering in 
participants randomized to standard glycemia therapy 
(HR = 0.79, 95% CI 0.65–0.96). These long-term results 
of the ACCORD trial do take on enhanced importance 
when viewed alongside the SPRINT results.
Several differences in the design of the studies may 
also explain the different results. ACCORD had lower 
event rates than initially predicted because of a lower 
CV risk profile in participants. The exclusion of partici-
pants aged >80 years led to a younger group of patients in 
ACCORD than in SPRINT. The mean age for ACCORD 
was 62 years and for SPRINT was 68 years.
Participants in the BP arm of the ACCORD were also 
at lower risk because patients with dyslipidemia were 
assigned to the lipid arm and were excluded from the BP 
arm.
Another significant difference in the design of the 
SPRINT and ACCORD studies was the use of diuretics. 
The treatment regimen for hypertension in the ACCORD 
study often used hydrochlorthiazide, and the SPRINT 
study primarily used chlorthalidone.
In addition, the complexity of the factorial study design 
in ACCORD may have made it less likely that a statisti-
cally significant difference could be demonstrated. This 
may suggest that if diabetic patients were included in 
the SPRINT they would also benefit from intensive BP 
lowering.
When we try to explain the reason for the difference 
between the SPRINT and the ACCORD it should be 
emphasized that the results of the SPRINT are provoca-
tive. In the recent Heart Outcomes Prevention Evalua-
tion (HOPE)–3 trial 12,705 participants at intermediate 
risk who did not have CV disease were randomized to 
receive either candesartan at a dose of 16  mg per day 
plus hydrochlorothiazide at a dose of 12.5  mg per day 
or placebo and were followed for 5.6  years. The first 
co-primary outcome was the composite of death from 
CV causes, nonfatal myocardial infarction, or nonfa-
tal stroke; the second co-primary outcome addition-
ally included resuscitated cardiac arrest, heart failure, 
and revascularization. Therapy with candesartan plus 
hydrochlorothiazide was not associated with a lower 
rate of major CV events than placebo despite a BP 
decrease of 6.0/3.0 mmHg in the active treatment group. 
The only subgroup who benefited from BP lowering 
was the subgroup of participants with initial systolic 
BP  >  143.5  mmHg [44]. A recent study that used the 
extended follow-up data from the US cohort of the Inter-
national Verapamil [SR]/Trandolapril Study (INVEST) 
showed that in hypertensive patients with coronary 
artery disease, achieving a systolic BP of 130–140 mmHg 
seems to be associated with lower all-cause mortal-
ity after approximately 11.6  years of follow-up [45]. 
Similarly, the Secondary Prevention of Small Subcorti-
cal Strokes (SPS3) trial) evaluated BP goals in patients 
with a previous lacunar stroke testing a systolic goal of 
130–149 mmHg versus <130 mmHg [46]. This trial also 
did not demonstrate significant reductions in ischemic 
stroke or intracranial hemorrhage in the more intensive 
treated group. Why the results of the SPRINT showed 
a clear benefit of lowering systolic BP to  <120  mmHg 
whereas other studies failed to show it?
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One explanation is the technique of BP measurements. 
In the SPRINT, BP was measures with an automated 
oscillometric office BP method that eliminated the need 
for a human to participate in the actual measurement and 
therefore reduces the white coat effect. Compared with a 
reasonably well-done standard office-based BP, the use of 
an automated oscillometric office BP method will yield a 
systolic BP that is 7–10 mmHg lower in the same patient, 
measured on the same day. If this is true the systolic BP 
of 120  mmHg in the SPRINT is equivalent to almost 
130  mmHg in clinical practice. Thus, it is reasonable to 
suggest in high risk patients a target systolic BP of <130 
rather than <120 mmHg.
To solve the discrepancy between the various studies 
and to find out what should be the target systolic BP sev-
eral meta- analysis were recently published (Table 1).
A meta-analysis of 49 trials including 73,738 patients 
(most of them diabetic) showed that at BP values greater 
than 140  mmHg, BP reduction was associated with a 
decrease in mortality and CV morbidity. On the other 
hand, BP reduction in patients with initial BP val-
ues  <140  mmHg resulted in increased CV mortality and 
a tendency towards increased overall mortality [47]. 
Another meta-analysis evaluated randomized controlled 
trails performed only in diabetic individuals and concluded 
that the present evidence does not support BP targets 
lower than the standard targets in people with elevated BP 
and diabetes [48]. A recently published meta-analysis eval-
uated BP lowering for prevention of CV disease and death 
and reported that the proportional reduction in major CV 
disease events by BP reduction seemed to be larger in tri-
als done in people without diabetes or chronic kidney dis-
ease [49]. This was attributed to different methodological 
characteristics in studies in diabetic patients. Another 
meta-analysis of 13 randomized control studies includ-
ing over 37,000 diabetic hypertensive patients has shown 
that intensive systolic BP control to less than 130 mmHg 
was associated with a 10% reduction in all-cause mortality, 
yet no effects on microvascular or macrovascular events 
were noted. Regarding stroke, such an intensive BP reduc-
tion has led to a 17% risk reduction, accompanied by an 
additional risk reduction with further lowering systolic 
BP to <120 mmHg, without an increased risk for adverse 
effects [50]. Another meta-analysis included 31 rand-
omized control studies with over 73,000 diabetic hyper-
tensive patients reported a 31% reduction in relative risk of 
stroke, with a 13% reduction for every 5 mmHg systolic BP 
or 2 mmHg diastolic BP reductions. The risk of myocardial 
infarction was not significantly reduced with a more inten-
sive BP control [51].
Thus it seems that a target of systolic BP < 130 mmHg 
is reasonable in most diabetic patients. In elderly diabetic 
patients (>80  years) but otherwise healthy, a BP target 
of  <140–150/90  mmHg is reasonable. Lower BP levels 
may be adequate if tolerated by the patients. BP levels 
should be monitored closely in the sitting and the stand-
ing position and the treatment should be tailored to pre-
vent excessive fall in BP [52].
Treatment goals according to current guidelines
Although previous guidelines recommended strict BP 
control in diabetic patients [53, 54], this has been chal-
lenged in recent guidelines (Table 2). The British National 
Institute for Health and Clinical Excellence (NICE) 
guidelines published in 2011 [55] recommended com-
mencing treatment in diabetic patients with stage 1 
hypertension (Clinic BP  >  140/90  mmHg and ambula-
tory BP monitoring (ABPM) daytime average or home 
BP monitoring (HBPM) average BP of  >135/85  mmHg). 
The recently published 2016 American Diabetes Asso-
ciation (ADA) guidelines recommended that hyperten-
sive diabetic patients be treated if they have a diastolic BP 
of  >80  mmHg or a systolic BP  >  140  mmHg, with a tar-
get BP value of <140/90 mmHg [6]. These guidelines state 
that individuals in whom stroke risk is a concern may, as 
part of shared decision making, have lower systolic tar-
gets such as 130 mmHg. This is especially true if lower BP 
can be achieved with few drugs and without side effects of 
therapy. The American Heart association (AHA)/Ameri-
can College of Cardiology (ACC) guidelines from 2014 
recommend a target BP of <140/90 mmHg, but point out 
that lower targets may be considered [56]. The American 
Society of Hypertension (ASH)/International Society of 
Hypertension (ISH) guidelines from 2014 suggest a BP goal 
of  <140/90  mmHg in diabetic patients [2]. These values 
are lower than those recommended by the majority of the 
JNC 8 panel for non-diabetic patients aged 60–79, which 
was  <150/90  mmHg, yet similar to those recommended 
for non-diabetics aged 18–60  years, and similar to the 
values of all non-diabetic patients by the minority view of 
the JNC8 [1]. The 2013 European Society of Hypertension 
(ESH) and European Society of Cardiology (ESC) guide-
lines recommend lowering systolic BP below 140 mmHg, 
and diastolic BP below 85  mmHg [3]. The Canadian 
Hypertension Education Program (CHEP) suggests a tar-
get BP of <130/80 mmHg [7]. The International Diabetes 
Federation (IDF) suggests age-adjusted BP targets (BP tar-
get values of <130/80 mmHg for diabetic patients younger 
than 70 years, target values of <140/90 mmHg for patients 
70–80 years old, and target values of <150/90 mmHg for 
patients over 80 years old) [5].
How to reach goal blood pressure in diabetics
Non‑pharmacological treatment
Non-pharmacological anti-hypertensive therapy 
includes weight loss, increased potassium-based diet 
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(DASH- dietary Approach to Stop Hypertension- style 
diet), low sodium consumption (below 2400  mg/day), 
moderation of alcohol intake and regular physical activity 
and exercise. Although the CV benefits of lifestyle inter-
ventions were not evaluated in diabetic patients, their 
implementation seems reasonable in diabetics since they 
may positively affect glycemia and lipid profile. There-
fore their adoption for all diabetic patients with BP val-
ues  >120/80  mmHg was recommended by recent ADA 
standards of care [6].
Pharmacological treatment
Renin‑angiotensin‑aldosterone blockers
Angiotensin converting enzyme inhibitors (ACEI), and 
angiotensin receptor blockers (ARBs) have long been 
considered the cornerstone of anti-hypertensive treat-
ment in diabetic patients. Previous studies have demon-
strated that both renin-angiotensin-aldosterone system 
(RAAS) blockers, ACEI and ARB, are associated with 
prevention of new onset DM in hypertensive patients 
[57] and are particularly favorable among patients with 
albuminuria [57]. Although ACEIs were reported to 
reduce overall CV risk, overt nephropathy, renal fail-
ure and retinopathy among non-hypertensive diabetics, 
other studies failed to show the superiority of ACEI over 
beta blockers in lowering BP and preventing nephropa-
thy or retinopathy in diabetic patients [58, 59]. Despite 
the fact that ACEIs were found to be superior to ARBS 
in preventing all-cause mortality and CV morbidity and 
mortality in two meta-analysis [60, 61], in the ONTAR-
GET study, outcome was similar between the two drug 
classes [34] and in a recent real-world study ARBS were 
found to be more effective than ACEI in the prevention 
of stroke [62]. Therefore it seems that ACEIs and ARBs 
are probably equally efficacious for the prevention of CV 
outcomes in hypertensive diabetics. ARBs and ACEIs 
are equally effective in preventing progression of kidney 
disease in diabetic patients with early nephropathy with 
ARBS having comparable BP lowering capacity with 
fewer side effects compared with ACEIs [63]. In a recent 
study that compared the BP lowering effect of ARBs in 
diabetic patients, azilsartan medoxomil was more effec-
tive than olmesartan and valsartan [64]. A recent meta-
analysis of 19 randomized controlled trials with over 
25,000 participants found that ACEIs or ARBs were asso-
ciated with a similar risk of death (relative risk 0.99, 95% 
CI 0.93–1.05), CV death (1.02, 0.83–1.24), myocardial 
infarction (0.87, 0.64–1.18), angina pectoris (0.80, 0.58–
1.11), stroke (1.04, 0.92–1.17), heart failure (0.90, 0.76–
1.07), revascularization (0.97, 0.77–1.22) and end stage 
renal disease (0.99, 0.78–1.28) as compared with other 
anti-hypertensive agents [65]. Combining two RAAS 
blockers is discouraged based on the discouraging results 
of the Aliskiren Trial in Type 2 Diabetes Using Cardio-
renal Endpoints (ALTITUDE) and the ONTARGET trials 
[34, 66]. In summary, it seems that use of ACEIs or ARBs 
is not superior to use of other anti-hypertensive agents 
in diabetics without evidence of nephropathy, but these 
classes are legitimate first-line treatment options in the 
absence of contraindications.
Beta blockers
The use of beta blockers has been discouraged in diabetic 
patients due to its potential adverse metabolic effects, 
including an increase in triglyceride levels, a decrease in 
HDL cholesterol levels, weight gain, masking hypoglyce-
mia and impairing insulin sensitivity [67]. In addition, it 
has been suggested that use of beta blockers in non-dia-
betic individuals, particularly those who are overweight 
or obese, might increase the risk for development of dia-
betes compared with an alternative agent [68]. As beta 
blockers are being used infrequently as first-line agents 
for the treatment of hypertension, their use in diabetes 
is also infrequent, but beta blockers may still be used as 
add-on treatment in those who require multiple agents 
and in patients in whom another indication for the use of 
beta blockers is present, such as those with tachycardia, 
heart failure or ischemic heart disease [1, 3].
Calcium channel blockers (CCBs)
CCBs are considered a potential first-line treatment for 
hypertensive diabetics, particularly in the elderly with 
isolated systolic hypertension [69]. CCBs have been 
shown to be particularly effective in the prevention of 
stroke, but are less effective than RAAS blockers in pre-
vention of heart failure [70]. Although non-dihydropyri-
dines decrease urinary protein excretion and serve as an 
alternative in RAAS inhibitor-intolerant patients [71], 
most research in recent years has focused on the efficacy 
and safety of dihydropyridines. The Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT BPLA) compared use 
of atenolol with amlodipine and found that amlodipine 
was more effective than atenolol in reducing stroke, CV 
events and all-cause mortality [67]. This advantage of 
amlodipine was evident in the large group of 5137 dia-
betics included in the study [72]. Notably, an ACEI was 
added to the amlodipine arm when BP was not con-
trolled, whereas in the atenolol arm, a thiazide was added. 
A systematic review from 2015 evaluated the efficacy of 
amlodipine in the treatment of patients with  hyperten-
sion with concomitant  DM  and/or renal dysfunction 
compared with other classes of antihypertensive medi-
cation and found that amlodipine was at least as effec-
tive as other anti-hypertensive agents in the treatment 
of hypertension, was associated with a decrease in stroke 
risk and an increase in heart failure risk [73]. CCBs are 
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ineffective for the prevention of diabetes in non-diabetic 
individuals [74]. In summary, CCBs may be used as first-
line agents for the treatment of hypertension in diabetic 
individuals, particularly in the elderly with isolated sys-
tolic hypertension.
Diuretics
Although there has been concern that diuretics might 
increase the risk for the development of diabetes mel-
litus [75] due to their potential to negatively influence 
insulin resistance [76], diuretics are important agents 
used for the treatment of hypertension in diabetics. In a 
sub-analysis of the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT), 
chlortalidone was found to be as good as amlodipine 
or lisinopril in preventing fatal and non-fatal coronary 
artery disease and was more effective in the prevention 
of heart failure in diabetic patients [77]. The benefits of 
diuretics were also observed in the SHEP trial [78, 79]. In 
all studies in which diuretics were found to be effective 
in hypertensive diabetics, chlorthalidone or indapamide 
were used. To summarize, diuretics may be used for the 
treatment of hypertension in diabetics either as first line 
agents or as add-on treatment, but glucose and electro-
lytes should be monitored when initiating therapy.
Alpha blockers
There are no specific studies which evaluated the efficacy 
of alpha blockers in diabetic patients. Alpha blockers do 
not adversely affect glucose metabolism or lipid profile, 
but they have been reported to be less effective than chlo-
rthalidone for prevention of stroke and heart failure [80, 
81] and therefore are used almost exclusively in patients 
with hypertension and prostate hyperplasia or as third or 
fourth-line agents.
Aldosterone antagonists
Low dose spironolactone was found to be effective in 
controlling BP in patients with hypertension and diabetes 
[82]. The addition of spironolactone is particularly effec-
tive in those with serum potassium of <4.5 mmol/L [83]. 
To prevent hyperkalemia thiazide or thiazide like diuret-
ics should be continued when aldosterone antagonists 
are added [84]. The addition of spironolactone to con-
ventional antihypertensive treatment in diabetic patients 
was shown to reduce albuminuria [85] and in diabetic 
patients with albuminuria, addition of an aldosterone 
antagonist to an ACEI has been shown to have renopro-
tective effects superior to those shown with the addition 
of an ARB, even when BP reduction rates were similar 
[86]. Finerenone is a new non-steroidal anti mineralo-
corticoid which has less relative affinity than spironolac-
tone and eplerenone to other steroid hormone receptors, 
and therefore has less adverse effects like gynaecomastia, 
impotence, low sex drive and hyperkalemia. A recent 
study showed that in patients with diabetic nephropathy 
the addition of finerenone to an angiotensin-converting 
enzyme inhibitor or an angiotensin receptor blocker 
improved urinary albumin-creatinine ratio better than 
placebo [87]. It seems that aldosterone antagonists have 
a renoprotective effect that is independent of systemic 
hemodynamic alterations [88]. Diabetic individuals tend 
to develop type 4 renal tubular acidosis and therefore 
hyperkalemia may be a concern in those treated with 
aldosterone antagonists, particularly when combined 
with ACEIs or ARBs, although the long-term risk is low 
[89].
Combination therapy
More than two-thirds of hypertensive individuals are 
inadequately controlled on mono therapy [90]. Most 
diabetic individuals are treated with RAAS inhibi-
tors and most guidelines recommend adding a calcium 
antagonist or diuretic as add-on therapy [1, 5, 6]. In a 
sub-analysis of 6946 diabetic patients, in the Avoiding 
cardiovascular Events through combination Therapy in 
Patients Living with Systolic Hypertension (ACCOM-
PLISH) trial, a combination of benazepril plus amlodi-
pine was significantly more effective in reducing the 
composite of CV death, nonfatal myocardial infarction, 
nonfatal stroke, hospitalization for angina, resuscita-
tion after sudden cardiac arrest, and coronary revas-
cularization, compared to therapy with benazepril plus 
hydrochlorothiazide [42]. The superiority of amlodipine 
over hydrochlorothiazide as an addition to benazepril 
disappeared in obese individuals [91]. Combining a 
RAAS blocker with a CCB provides better renopro-
tection and leads to less ankle edema compared with a 
CCB alone [92]. In addition, combining an ARB with 
a CCB was associated with improved insulin sensitiv-
ity compared with an ARB and a diuretic [93]. Based 
on these studies, it seems that CCBs are appropriate as 
second-line agents in diabetic patients already treated 
with RAAS blockers. In obese individuals or when vol-
ume overload is present, diuretics may be used as well. 
In a large group of patients with stage I hypertension a 
combination of chlorthalidone and amiloride yielded a 
greater reduction in BP than the ARB losartan [94]. In 
patients requiring triple therapy, RAAS blockers should 
be combined with diuretics and CCBs, unless there is 
compelling indication for the use for a different anti-
hypertensive class (heart failure or ischemic heart dis-
ease for beta blockers or benign prostate hyperplasia for 
alpha blockers). Patients with resistant hypertension, 
particularly in the presence of low potassium levels, 
may benefit from aldosterone antagonists. These should 
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be used cautiously, particularly in patients already on 
RAAS blockers. Once BP goal has been achieved anti-
hypertensive treatment should be continued. In the 
ADVANCE trial discontinuation of antihypertensive 
medications was associated with increased risk of com-
bined macro and microvascular events [95].
Diabetic treatment effective for the control 
of hypertension
In the last decade there is a surge of new anti-diabetic 
medications working on different pathways in insulin 
production and glucose disposal. Some of these agents 
have beneficial effects on BP and may prove as important 
agents for the control of hypertension in diabetic indi-
viduals. In this paragraph we will discuss these classes of 
agents and the evidence for their effect on elevated BP in 
both normotensive and hypertensive individuals.
Glucagon‑like‑polypeptide 1 analogues
Glucagon-like-polypeptide 1 analogues (GLP1a) lead to 
a clinically significant weight loss in both diabetics and 
non-diabetics [96, 97] and thus may aid in a better BP 
control. On the other hand, they have been reported to 
increase heart rate through sympathetic nervous system 
activation [98] and this may result in BP elevation. In the 
recently published Liraglutide Effect and Action in Dia-
betes: Evaluation of Cardiovascular Outcome Results 
(LEADER) trial [99], patients treated with liraglutide had 
a mild decrease in systolic BP (1.5  mmHg) and a mild 
increase in diastolic BP (0.6 mmHg). In the trial to evalu-
ate CV and other long-term outcomes with Semaglutide 
in Subjects with Type 2 Diabetes (SUSTAIN-6) in which 
the CV safety of semaglutide was evaluated [100], the 
mean systolic BP in the semaglutide group, as compared 
with the placebo group, was 1.3  mmHg lower in the 
group receiving 0.5 mg (P = 0.10) and 2.6 mmHg lower 
in the group receiving 1.0  mg (P  <  0.05). Thus it seems 
the GLP1a have a neutral effect on BP and may even 
result in a mild decrease in BP, but probably cannot serve 
as an alternative to anti-hypertensive treatment in hyper-
tensive diabetics.
Dipeptidyl peptidase‑4 (DPP4) inhibitors
DPP4 inhibitors elevate endogenous GLP1 through 
inhibition of the endogenous substance responsible 
for its degradation. Several studies reported that these 
agents produce a modest decrease in BP [101–103], oth-
ers reported that they increase BP [104] and yet others 
reported that they negate the hypotensive effects of ACEI 
[105]. Overall it seems that DPP4 inhibitors are neutral in 
term of BP control and their initiation probably does not 
significantly affect BP control.
Sodium‑glucose‑ transporter 2 (SGLT2) inhibitors
Three representatives of this new class of anti-diabetics 
are currently in the market-canagliflozin, dapagliflozin 
and empagliflozin. Some others are under development. 
Although agents differ in their affinity for the sodium-
glucose transporter, their clinical efficacy is quite simi-
lar. All three have similar efficacy in terms of glucose 
control and all are associated with significant weight 
loss [106]. All three have been reported to significantly 
decrease systolic and diastolic BP by 3–5/2–3  mmHg 
[107]. A meta-analysis published in 2014 reported that 
SGLT2 inhibitors decrease systolic and diastolic BP 
by 4 and 1.6  mmHg compared with placebo [108]. A 
pooled analysis of studies of canagliflozin and dapagli-
flozin concluded that orthostatic hypotension was not 
increased during treatment with these SGLT2 inhibitors 
compared with placebo. Three independent studies pub-
lished after this meta-analysis specifically evaluated the 
effect of SGLT2 inhibitors on BP in diabetic individuals. 
The dapagliflozin BP study [109] reported a 4.28 mmHg 
statistically significant decrease in seated systolic BP 
during a 12-week period compared with placebo and a 
non-statistically significant decrease in diastolic BP com-
pared with placebo. Orthostatic hypotension was not 
increased in the treatment arm compared with placebo. 
In another study Weber MA et al. showed a 3.1 mmHg 
fall in seated systolic BP and 2.9 mmHg fall in systolic BP 
recorded by 24H ambulatory blood pressure monitor-
ing after 12  weeks of treatment with dapagliflozin[110]. 
The Empagliflozin Cardiovascular Outcome Event Trial 
in Type 2 Diabetes Mellitus Patients (EMPA-REG) BP 
study [111] reported that mean systolic BP as evaluated 
by ambulatory BP monitoring was significantly lower in 
patients treated with both 10  and 25  mg empagliflozin 
compared with placebo. Patients who entered the study 
with uncontrolled hypertension had a more significant 
response to empagliflozin compared with those in which 
BP was well controlled prior to study initiation. Orthos-
tatic hypotension was more prevalent in the empagliflo-
zin group, but none of the patients who had orthostatic 
hypotension experienced clinical events related to this 
finding, making its clinical significance questionable. The 
canagliflozin BP study was the smallest of the three stud-
ies [112] and reported findings consistent with the previ-
ously mentioned studies with a decrease in systolic BP as 
assessed by ambulatory BP monitoring of approximately 
2 mmHg for both 100 and 300 mg. Orthostatic hyperten-
sion as assessed by ambulatory BP monitoring or through 
clinical symptoms occurred only in the canagliflozin 
group. It is important to note that patients enrolled to all 
three studies of SGLT2 inhibitors in hypertensive diabet-
ics were Caucasian and data evaluating the influence of 
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SGLT inhibitors on BP in diabetics of non-Caucasian ori-
gin is much less extensive.
In addition, these drugs were reported to have a posi-
tive effect on the circadian rhythm in rats who devel-
oped hypertension [113]. The mechanism underlying the 
BP decrease by SGLT2 inhibitors is unclear and poten-
tial mechanisms include diuresis, nephron remodeling, 
decrease in arterial stiffness, and weight loss [114]. This 
class of agents is certainly promising as it can be used to 
control glucose, weight and BP. In fact, the EMPA-REG 
trial indeed showed that empagliflozin is associated with 
decreased CV morbidity, CV mortality and overall mor-
tality [115]. Several potential non-glycemic mechanisms 
such as BP decrease and weight reduction have been 
suggested to explain the CV benefit of SGLT2 (Fig.   1). 
Whether SGLT2 inhibitors can be used for BP control 
in non-diabetic individuals is unclear. The results of the 
Canagliflozin Cardiovascular Assessment Study (CAN-
VAS) [116] and DECLARE-TIMI 55 (for dapagliflozin) 
[117] studies which are expected to be complete on 2017 
and 2019 respectively will clarify whether the CV bene-
fits reported for empagliflozin are a class-effect.
Conclusions
Current evidence does not support a more stringent BP 
control strategy for all diabetic patients and the evidence 
to support stringent control in certain diabetic patients is 
also inconclusive. In elderly diabetic patients (>80  years) 
BP levels should be less than 140–150/90  mmHg and 
should be monitored closely in the sitting and the standing 
position and the treatment should be tailored to prevent 
excessive fall/decrease in BP. This is reflected in recom-
mendations in most current BP treatment guidelines. The 






























Fig. 1 Beneficial effects of SGLT2 inhibitors, SNS, sympathetic nervous system; LDL-c, low density lipoprotein cholesterol; HDL, high density lipopro-
tein cholesterol
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evidence although RAAS blockers are usually used as first-
line agents. When requiring more than one agent for the 
control of hypertension in diabetics, calcium antagonists 
or diuretics are probably appropriate as second line agents. 
New agents used for the treatment of diabetes may aid 
in the control of hypertension and a diagnosis of hyper-
tension in a diabetic person may influence the clinician’s 
choice to use a certain anti-diabetic treatment.
In addition to lowering BP it is very important to con-
trol all other risk factors in diabetic patients. This het-
erogeneous treatment model, relates directly to general 
trends in modern medicine, reflecting an aspiration for 
individually tailored medicine, adapted specifically for 
the particular demographic and biologic characteristics 
of each patient.
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